Clinical Trial Update: A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating topical BX005-A for moderate to severe Atopic Dermatitis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• BX005-A

Snippet

Sponsor: BiomX, Inc. | Conditions: Atopic Dermatitis | Phase 1, Phase 2 | Status: WITHDRAWN